Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date
97 hot topic(s) found with the query "Schizophrenia"

Clinical implementation of preemptive pharmacogenomics in psychiatry.
Maria Skokou et al. EBioMedicine 2024 2 105009 (Posted: Feb 18, 2024 7AM)

From the abstract: "We report our findings from a multicenter, large-scale, prospective study of pre-emptive genome-guided treatment named as PREemptive Pharmacogenomic testing for preventing Adverse drug REactions (PREPARE) in a large cohort of psychiatric patients (n = 1076) suffering from schizophrenia, major depressive disorder and bipolar disorder.We show that patients with an actionable phenotype belonging to the PGx-guided arm (n = 25) present with 34.1% less adverse drug reactions compared to patients belonging to the control arm (n = 36), 41.2% less hospitalisations (n = 110 in the PGx-guided arm versus n = 187 in the control arm) and 40.5% less re-admissions (n = 19 in the PGx-guided arm versus n = 32 in the control arm). "

Medical AI falters when assessing patients it hasn’t seen
M Nadaf, Nature, January 11, 2024 (Posted: Jan 12, 2024 6AM)

From the article: "Computer algorithms that are designed to help doctors treat people with schizophrenia do not adapt well to fresh, unseen data, a study has found. Such tools — which use artificial intelligence (AI) to spot patterns in large data sets and predict how individuals will respond to a particular treatment — are central to precision medicine, in which health-care professionals try to tailor treatment to each person. "

Multigenetic Pharmacogenomics-Guided Treatment vs Treatment As Usual Among Hospitalized Men With Schizophrenia: A Randomized Clinical Trial.
Zhewei Kang et al. JAMA Netw Open 2023 10 (10) e2335518 (Posted: Oct 07, 2023 8AM)

From the abstract: "What is the therapeutic efficacy of multigenic pharmacogenomics–guided treatment in patients with schizophrenia? In this randomized clinical trial that included 210 Chinese Han men, patients treated with multigenetic pharmacogenomics–guided treatment had a greater symptom improvement than those treated with treatment as usual after a 6-week treatment, measured as the mean difference in percentage change of Positive and Negative Syndrome Scale score. Meaning Multigenetic pharmacogenomic testing can be an effective tool to guide the treatment of schizophrenia. "

Schizophrenia Linked With Genetic Changes That Are Not Inherited.
Emily Harris et al. JAMA 2023 7 (Posted: Jul 21, 2023 7AM)

Previous research has linked heritable genetic changes with schizophrenia. But genetic changes that occur in utero and are not inherited might also be associated with developing schizophrenia later, according to new data from more than 24?000 people with and without the condition. The study found that deletions in 2 genes were more common in people with schizophrenia. The first gene, NRXN1, encodes a protein involved in brain signaling. The second, ABCB11, is enriched in dopaminergic neurons in a subset of people with treatment-resistant schizophrenia who were taking clozapine,

Deep Clinical Phenotyping of Schizophrenia Spectrum Disorders Using Data-Driven Methods: Marching towards Precision Psychiatry
TD Haptewold et al, J Per Med, June 5, 2023 (Posted: Jun 05, 2023 8AM)

This article provides an overview of findings from the Genetic Risk and Outcome of Psychosis (GROUP) cohort study on the deep clinical phenotyping of schizophrenia spectrum disorders targeting positive and negative symptoms, cognitive impairments and psychosocial functioning. Three to four latent subtypes of positive and negative symptoms were identified in patients, siblings and controls, whereas four to six latent cognitive subtypes were identified. Five latent subtypes of psychosocial function—multidimensional social inclusion and premorbid adjustment—were also identified in patients.

How one man's rare Alzheimer’s mutation delayed the onset of disease Genetic resilience found in a person predisposed to early-onset dementia could potentially lead to new treatments.
S Reardon, Nature, May 16, 2023 (Posted: May 16, 2023 9AM)

The researchers found that the man had a mutation in a gene coding for a protein called reelin, which is associated with brain disorders including schizophrenia and autism. Little is known about reelin’s role in Alzheimer’s. The study challenges the theory that Alzheimer’s disease is primarily driven by amyloid plaques, which are the targets of several drugs recently approved by the US Food and Drug Administration. The drugs effectively remove amyloid from the brain, but lead to only a moderate improvement in rates of cognitive decline.

The Progress and Pitfalls of Pharmacogenetics-Based Precision Medicine in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis
Y Teng et al, J Per Med, March 4, 2023 (Posted: Mar 04, 2023 8AM)

The inadequate efficacy and adverse effects of antipsychotics severely affect the recovery of patients with schizophrenia spectrum disorders (SSD). We report the evidence for associations between pharmacogenetic (PGx) variants and antipsychotics outcomes, including antipsychotic response, antipsychotic-induced weight/BMI gain, metabolic syndrome, antipsychotic-related prolactin levels, antipsychotic-induced tardive dyskinesia (TD), clozapine-induced agranulocytosis (CLA), and drug concentration level (pharmacokinetics) in SSD patients.

Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia.
Bochao D Lin et al. JAMA psychiatry 2022 12 (2) 181-185 (Posted: Feb 02, 2023 6AM)

Are polygenic risk scores for schizophrenia (PRS-SCZ) associated with a psychosis liability spectrum and a clinician’s decision to prescribe clozapine? In this genetic association study with 2344 participants from 2 cohorts, we found that PRS-SCZ loading was highest among individuals with schizophrenia spectrum disorders taking clozapine, followed by those taking other antipsychotics, their relatives, and unrelated healthy controls. In addition, PRS-SCZ was positively associated with a clozapine prescription relative to other antipsychotics.

Ribosomal DNA Abundance in the Patient’s Genome as a Feasible Marker in Differential Diagnostics of Autism and Childhood-Onset Schizophrenia
ES Ershova et al, J Per Med, October 31, 2022 (Posted: Oct 31, 2022 9AM)

The controversial embryo tests that promise a better baby Some companies offer tests that rank embryos based on their risk of developing complex diseases such as schizophrenia or heart disease. Are they accurate — or ethical?
M Koslov, Nature, September 21, 2022 (Posted: Sep 22, 2022 6AM)

Pre-implantation genetic testing (PGT) for rare genetic disorders and chromosomal abnormalities has become common practice in the US$14-billion IVF industry. But testing for polygenic conditions (often referred to as PGT-P) is much newer, with only a small handful of companies selling it in a few countries, including the United States and Brazil, where it is largely unregulated.

Diverse mutations in autism-related genes and their expression in the developing brain
Nature Genetics, August 18, 2022 (Posted: Aug 18, 2022 1PM)

Across >150,000 individuals, we identified hundreds of genes associated with autism spectrum disorder (ASD) and atypical neurodevelopment. Most ASD-related genes were also associated with developmental delay. However, increased mutation rates in ASD and shared genetic risk with schizophrenia was observed for some genes, many of which are enriched in developing neurons.

Ultrarare Coding Variants and Cognitive Function in Schizophrenia—Unraveling the Enduring Mysteries of Neuropsychiatric Genetics
DL Braff et al, JAMA Psychiatry, August 17, 2022 (Posted: Aug 17, 2022 5PM)

For neuropsychiatric genomics the big picture is that we are looking at a spectrum of common and rare (and ultrarare) variations to understand a whole-brain disorder that seems to involve a complex tapestry encompassing both cortical and subcortical dysfunctions. Synthesizing these findings into a coherent functional neurobiological model of schizophrenia will be our formative challenge.

Exploring Links Between Psychosis and Frontotemporal Dementia Using Multimodal Machine Learning: Dementia Praecox Revisited.
Koutsouleris Nikolaos et al. JAMA psychiatry 2022 8 (Posted: Aug 05, 2022 8AM)

In this diagnostic/prognostic study including 1870 patients, patients with schizophrenia expressed the neuroanatomical pattern of behavioral-variant frontotemporal dementia more strongly (41%) than that of Alzheimer disease (17%), and at lower levels, this difference was also encountered in those with major depression (22% vs 3%). Already in clinical high-risk states for psychosis the high expression of the behavioral-variant frontotemporal dementia pattern was linked to severe phenotypes, unfavorable courses, and elevated polygenic risks for schizophrenia and dementia, with further pattern progression being present in those patients who did not recover over time.

The performance of artificial intelligence-driven technologies in diagnosing mental disorders: an umbrella review
A Abd-Alrazak et al, NPJ Digital Medicine, July 7, 2022 (Posted: Jul 08, 2022 7AM)

We included 15 systematic reviews of 852 citations identified. The included reviews assessed the performance of AI models in diagnosing Alzheimer’s disease (n?=?7), mild cognitive impairment (n?=?6), schizophrenia (n?=?3), bipolar disease (n?=?2), autism spectrum disorder (n?=?1), obsessive-compulsive disorder (n?=?1), post-traumatic stress disorder (n?=?1), and psychotic disorders (n?=?1). The performance of the AI models in diagnosing these mental disorders ranged between 21% and 100%. AI technologies offer great promise in diagnosing mental health disorders. The reported performance metrics paint a vivid picture of a bright future for AI in this field.

miRNAs as potential diagnostic biomarkers and pharmacogenomic indicators in psychiatric disorders.
Tsermpini Evangelia Eirini et al. The pharmacogenomics journal 2022 6 (Posted: Jun 28, 2022 7AM)

We provide herein a detailed overview of circulating miRNAs and their expression profiles as biomarkers in schizophrenia, bipolar disorder and major depressive disorder and their role in response to specific treatments. Bioinformatics analysis of miR-34a, miR-106, miR-134 and miR-132, which are common among SZ, BD and MDD patients, showed brain enrichment and involvement in the modulation of critical signaling pathways, which are often deregulated in psychiatric disorders. We propose that specific miRNAs support accurate diagnosis and effective precision treatment of psychiatric disorders.

Genetic origins of schizophrenia find common ground
CO Lyegbe et al, Nature, April 11,2022 (Posted: Apr 12, 2022 7AM)

There has long been debate about whether the genetic component of complex disorders, such as schizophrenia, is attributable mainly to rare or common DNA variants1. Two studies now provide evidence for key roles of both types of variant. The first study identified hundreds of common genetic variants that each have a tiny influence on schizophrenia risk. The second discovered a handful of rare variants, each of which have a large effect. Together, these studies show that common and rare genetic causes of illness might often disrupt the same biological processes that lead to disease.

Mapping genomic loci implicates genes and synaptic biology in schizophrenia
V Trubetskoy et al, Nature, April 8, 2022 (Posted: Apr 09, 2022 2PM)

In a two-stage genome-wide association study of up to 76,755 individuals with schizophrenia and 243,649 control individuals, we report common variant associations at 287 distinct genomic loci. Associations were concentrated in genes that are expressed in excitatory and inhibitory neurons of the central nervous system, but not in other tissues or cell types. Using fine-mapping and functional genomic data, we identify 120 genes (106 protein-coding) that are likely to underpin associations at some of these loci.

Rare coding variants in ten genes confer substantial risk for schizophrenia
T Singh et al, Nature, April 8, 2022 (Posted: Apr 09, 2022 2PM)

By meta-analysing the whole exomes of 24,248 schizophrenia cases and 97,322 controls, we implicate ultra-rare coding variants (URVs) in 10 genes as conferring substantial risk for schizophrenia (odds ratios of 3–50, P?<?2.14?×?10-6) and 32 genes at a false discovery rate of <5%. These genes have the greatest expression in central nervous system neurons and have diverse molecular functions that include the formation, structure and function of the synapse.

Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia.
Pardiñas Antonio F et al. JAMA psychiatry 2022 1 (3) 260-269 (Posted: Mar 03, 2022 8AM)

Can common genetic variants be used to differentiate between treatment-resistant schizophrenia (TRS) and other forms of this disorder? Data from this genome-wide association study including 85?490 participants were used to estimate genome-wide single-nucleotide variation effect size differences between individuals with and without TRS, which were compatible with a polygenic model of treatment resistance. Results were used to generate a polygenic risk score, which was significantly associated with TRS status in independent incidence and prevalence samples.

Evidence Used to Update the List of Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19
CDC Science Brief, October 14, 2021 Brand (Posted: Oct 16, 2021 8AM)

Chronic lung disease (including bronchiectasis, bronchopulmonary dysplasia, interstitial lung disease, pulmonary hypertension, pulmonary embolism, tuberculosis) and chronic liver disease (including cirrhosis, non-alcoholic fatty liver disease, alcoholic liver disease, and autoimmune hepatitis) were added September 2021 based on evidence published between December 1, 2019 and August 31, 2021 using the updated review methods outlined below. Mental health disorders (such as mood disorders including depression, and schizophrenia spectrum disorders) were added September 2021 based on evidence published between December 1, 2019 and August 31, 2021. No conditions were removed from the previous underlying medical conditions list.

Perturbations in Gut Microbiota Composition in Psychiatric Disorders: A Review and Meta-analysis.
Nikolova Viktoriya L et al. JAMA psychiatry 2021 9 (Posted: Sep 18, 2021 11AM)

This systematic review and meta-analysis found that gut microbiota perturbations were associated with a transdiagnostic pattern with a depletion of certain anti-inflammatory butyrate-producing bacteria and an enrichment of pro-inflammatory bacteria in patients with depression, bipolar disorder, schizophrenia, and anxiety.

What is pharmacogenomics?
CB de Villiers, PHG Foundation, August 2021 (Posted: Aug 26, 2021 7AM)

Pharmacogenomics, a branch of precision medicine, is the study of genomic characteristics that affect how individuals respond to drugs. It could be useful for improving treatment for a wide variety of conditions such as depression, schizophrenia, heart disease, diabetes, cancer, and infectious diseases.

Polygenic risk score analysis for amyotrophic lateral sclerosis leveraging cognitive performance, educational attainment and schizophrenia
R Restuadi et al, EJHG, April 27, 2021 (Posted: Apr 27, 2021 8AM)

Use of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia.
Gillespie Nathan A et al. JAMA psychiatry 2020 Nov (Posted: Nov 05, 2020 6AM)

We reviewed reports that used 4 genetic methods that address the nature of the cannabis-schizophrenia association. We evaluated 3 hypotheses. We conclude that the observed cannabis-schizophrenia association may arise from potential causal effect of cannabis on risk of schizophrenia, but an appreciable proportion of the association is not causal.

Mutations associated with neuropsychiatric conditions delineate functional brain connectivity dimensions contributing to autism and schizophrenia
CA Moreau et al, Nature Comms, October 19, 2020 (Posted: Oct 20, 2020 7AM)

16p11.2 and 22q11.2 Copy Number Variants (CNVs) confer high risk for Autism Spectrum Disorder (ASD), schizophrenia (SZ), and Attention-Deficit-Hyperactivity-Disorder (ADHD), but their impact on functional connectivity (FC) remains unclear. Here we report an analysis of resting-state FC using magnetic resonance imaging data from 101 CNV carriers, 755 individuals with idiopathic ASD, SZ, or ADHD and 1,072 controls.

Association of Recent Stressful Life Events With Mental and Physical Health in the Context of Genomic and Exposomic Liability for Schizophrenia
LK Pries et al, JAMA Psychiatry, August 11, 2020 (Posted: Aug 13, 2020 10AM)

Studying individual risk factors for self-harm in the UK Biobank: A polygenic scoring and Mendelian randomisation study
KX Lim et al, PLOS Medicine, June 1, 2020 (Posted: Jun 03, 2020 7AM)

We used data from UK Biobank participants to investigate 24 potential individual risk factors for self-harm.Out of these 24 risk factors, major depressive disorder, attention-deficit hyperactivity disorder and schizophrenia appeared to be the most plausible causal risk factors for self-harm.?

Precision psychiatry with immunological and cognitive biomarkers: a multi-domain prediction for the diagnosis of bipolar disorder or schizophrenia using machine learning
BS Fernandes et al, Translational Psychiatry, May 24, 2020 (Posted: May 26, 2020 7AM)

We developed a probabilistic multi-domain data integration model consisting of immune and inflammatory biomarkers in peripheral blood and cognitive biomarkers using machine learning to predict diagnosis of bipolar disorder and schizophrenia. 416 participants were included for blood, cognition and combined biomarkers analysis.

Predicting the first episode of psychosis
H Stower, Nature Medicine, May 13, 2020 (Posted: May 14, 2020 0PM)

Dynamic ElecTronic hEalth reCord deTection (DETECT) of individuals at risk of a first episode of psychosis: a case-control development and validation study
LL Raket et al, The Lancet Digital Health, May 2020 (Posted: May 14, 2020 0PM)

A novel recurrent neural network model was developed to predict the risk of first episode psychosis 1 year before the index date by employing demographics and medical events (in the categories diagnoses, prescriptions, procedures, encounters and admissions, observations, and laboratory test results) dynamically collected in the EHR as part of clinical routine.

First genomic study of schizophrenia in African people turns up broken genes
Nature News, February 3, 2020 (Posted: Feb 04, 2020 9AM)

Increased schizophrenia family history burden and reduced premorbid IQ in treatment-resistant schizophrenia: a Swedish National Register and Genomic Study
K Kowalek et al, Molecular Psychiatry, November 12, 2019 (Posted: Nov 12, 2019 8AM)

Intensive DNA search yields 10 genes tied directly to schizophrenia
J Kaiser, Science, October 25, 2019 (Posted: Oct 27, 2019 11AM)

By scouring the DNA of tens of thousands of people, gene hunters have for the first time nabbed a handful of rare genes that, when mutated, appear to be direct contributors to the disease—and may shed light on what goes awry in a schizophrenia patient’s brain.

Machine Learning for Suicide Research–Can It Improve Risk Factor Identification?
S Fazel et al, JAMA Psychiatry, October 23, 2019 (Posted: Oct 24, 2019 8AM)

Going forward, the development of prediction models in specific, high-risk groups (eg, US Army soldiers after psychiatric treatment10) or those with certain psychiatric diagnoses (eg, schizophrenia spectrum disorders11) will likely have benefits of higher accuracy, more acceptability to clinicians, and simpler linkage to interventions.

A large data resource of genomic copy number variation across neurodevelopmental disorders
Mehdi Zarrei, et al. Genomic Medcine, October 7, 2019 (Posted: Oct 10, 2019 8AM)

Multiple studies have attempted to identify shared etiology among NDDs, but this is the first genome-wide CNV analysis across autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), schizophrenia (SCZ), and obsessive-compulsive disorder (OCD) at once. The study found clinically relevant CNVs (broadly defined) in 284 (10.5%) of total subjects.

Genome-wide Association of Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia (COGS) Study
(Posted: Oct 10, 2019 8AM)

1789 patients with schizophrenia and HCPs of self-reported European or Latino ancestry were recruited through a collaborative effort across the COGS sites and genotyped using the PsychChip. The results suggest that the use of quantitative endophenotypes in genomic studies may provide an important, strong inference-based strategy for understanding the molecular basis of schizophrenia and may suggest novel treatment targets.

Penetrance and Pleiotropy of Polygenic Risk Scores for Schizophrenia in 106,160 Patients Across Four Health Care Systems.
Zheutlin Amanda B et al. The American journal of psychiatry 2019 Aug appiajp201918091085 (Posted: Aug 19, 2019 8AM)

The study demonstrates that an available measure of poly genetic risk for schizophrenia is robustly associated with schizophrenia in health care settings and has pleiotropic effects on related psychiatric disorders as well as other medical syndromes.

Schizophrenia Runs in My Family. What Does That Mean for Me and My Baby?
R Murray, NY Times, August 1, 2019 (Posted: Aug 05, 2019 8AM)

On the morning of my 25th birthday, I looked at the wall calendar from my spot in bed. I knew what turning 25 meant in my family. My mother, who has struggled with mental illness for the better part of her life, started hearing voices around the time she turned 25. Her paternal grandmother was a diagnosed schizophrenic. So was her biological father.

Pharmacological enrichment of polygenic risk for precision medicine in complex disorders
WR Reay et al, BiorxIV preprints, July 9, 2019 (Posted: Jul 09, 2019 9AM)

The authors developed a framework to quantify an individual's common variant enrichment in clinically actionable systems responsive to existing drugs. This was achieved with a metric designated the pharmagenic enrichment score (PES). They applied this approach to cases of schizophrenia and associated medications used.

Toward High Reproducibility and Accountable Heterogeneity in Schizophrenia Research.
Kochunov Peter et al. JAMA psychiatry 2019 Apr (Posted: Jul 07, 2019 0PM)

Schizophrenia is a neuropsychiatric illness with substantial individual variability. The heterogeneity spans most aspects of the illness: genetics, environmental risk factors, age at onset, symptoms, treatment response, and long-term prognosis. A new study shows brain heterogeneity in schizophrenia associated with polygenic risk score.

A Unique Genome-wide Association Study of a Psychiatric Disorder From India
VL Nimgaonkar et al, JAMA Psychiatry, July 3, 2019 (Posted: Jul 03, 2019 0PM)

Association of Schizophrenia Risk With Disordered Niacin Metabolism in an Indian Genome-wide Association Study
S Pariyasamy et al, JAMA Psychitary, July 3, 2019 (Posted: Jul 03, 2019 0PM)

Schizophrenia as a pseudogenetic disease: A call for more gene-environmental studies
EF Torrey et al, Psychiatric Research, June 2019 (Posted: Jun 13, 2019 1PM)

The use of pharmacogenetic testing in patients with schizophrenia or bipolar disorder: A systematic review.
Routhieaux Melanie et al. The mental health clinician 2018 Nov 8(6) 294-302 (Posted: Nov 07, 2018 11AM)

Genes, Environment and Schizophrenia: The Placenta is the Missing Link
Frontline Genomics, May 29, 2018 (Posted: May 30, 2018 4PM)

Schizophrenia ‘risk genes’ are not so risky if the mother’s pregnancy was healthy
S Begley, Stat News, May 28, 2018 (Posted: May 29, 2018 11AM)

Genetics researchers close in on schizophrenia
Cardiff University, Feb 26, 2018 (Posted: Feb 26, 2018 0PM)

Autism Shares Brain Signature with Schizophrenia and Bipolar Disorder- Gene expression patterns in the brains of people with these conditions, new research finds
Scientific American, Feb 8, 2018 (Posted: Feb 18, 2018 8AM)

The use of polygenic risk scores to identify phenotypes associated with genetic risk of schizophrenia: Systematic review.
Mistry Sumit et al. Schizophrenia research 2017 Nov (Posted: Dec 31, 2017 8AM)

Genetics of Schizophrenia: Ready to Translate?
Foley Claire et al. Current psychiatry reports 2017 Sep (9) 61 (Posted: Dec 31, 2017 8AM)

Genetics of Schizophrenia: Overview of Methods, Findings and Limitations.
Henriksen Mads G et al. Frontiers in human neuroscience 2017 322 (Posted: Jul 12, 2017 6PM)

Rethinking the Epigenetic Framework to Unravel the Molecular Pathology of Schizophrenia.
Cariaga-Martinez Ariel et al. International journal of molecular sciences 2017 04 (4) (Posted: May 03, 2017 6PM)

Proof of concept: Molecular prediction of schizophrenia risk
AR Docherty et al, May 2017, BioXRIV (Posted: May 03, 2017 6PM)

Schizophrenia and the dynamic genome
PF Sullivan, Genome Medicine, March 2, 2017 (Posted: Mar 05, 2017 3PM)

Genetics of schizophrenia: A consensus paper of the WFSBP Task Force on Genetics.
Giegling Ina et al. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2017 Jan 1-14 (Posted: Feb 27, 2017 9AM)

The Major Histocompatibility Complex (MHC) in Schizophrenia: A Review.
Mokhtari Ryan et al. Journal of clinical & cellular immunology 2016 Dec (6) (Posted: Feb 27, 2017 9AM)

Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia.
Van Lily et al. Current opinion in psychiatry 2017 Feb (Posted: Feb 27, 2017 9AM)

Changes in RNA splicing: a new mechanism for genetic risk in schizophrenia
Science Magazine, February 27, 2017 (Posted: Feb 27, 2017 9AM)

Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects
CNV and Schizophrenia Working Group, Nature Genetics, November 21, 2016 (Posted: Nov 21, 2016 1PM)

Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics.
Schmitt Andrea et al. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2016 Sep (6) 406-28 (Posted: Sep 25, 2016 8PM)

Reviewing the epigenetics of schizophrenia.
Cromby John et al. Journal of mental health (Abingdon, England) 2016 Aug 1-9 (Posted: Sep 25, 2016 8PM)

Phenomenology of Schizophrenia and the Representativeness of Modern Diagnostic Criteria.
Kendler Kenneth S et al. JAMA psychiatry 2016 Sep (Posted: Sep 25, 2016 8PM)

Genetic and epigenetic analysis of schizophrenia in blood—a no-brainer?
AE Jaffe et al, Genome Medicine, September 21, 2016 (Posted: Sep 25, 2016 7PM)

Runs in the Family
S Mukherjee, New Yorker, March 2016 (Posted: Mar 22, 2016 11AM)

Altering the course of schizophrenia: progress and perspectives.
Millan Mark J et al. Nature reviews. Drug discovery 2016 Mar (Posted: Mar 21, 2016 9AM)

Unravelling genetic risk of schizophrenia
Genomics Education Blog Post, March 20, 2016 (Posted: Mar 21, 2016 9AM)

Genetic study of schizophrenia returns the complement
A. Marson, Science Translational Medicine, February 24, 2016 (Posted: Feb 24, 2016 2PM)

Schizophrenia's strongest known genetic risk deconstructed
NIH News, January 27, 2016 Brand (Posted: Feb 02, 2016 8AM)

Scientists Move Closer to Understanding Schizophrenia’s Cause
B Carey, New York Times, January 27, 2016 (Posted: Feb 01, 2016 9AM)

Expert reaction to genetic association to schizophrenia
Science Media Center, January 27, 2016 (Posted: Jan 28, 2016 9AM)

Schizophrenia risk from complex variation of complement component 4
A Sekar et al, Nature, January 26, 2016 (Posted: Jan 28, 2016 7AM)

Scientists open the ‘black box’ of schizophrenia with dramatic genetic discovery
AE Nutt, Washington Post, January 27, 2016 (Posted: Jan 28, 2016 7AM)

The Schizophrenia Polygenic Risk Score: To What Does It Predispose in Adolescence?
KS Kendler, JAMA Psychiatry, January 27, 2016 (Posted: Jan 27, 2016 1PM)

Phenotypic Manifestation of Genetic Risk for Schizophrenia During Adolescence in the General Population
HJ JOnes et al, JAMA Psychiatry, January 27, 2016 (Posted: Jan 27, 2016 1PM)

New discoveries in schizophrenia genetics reveal neurobiological pathways: A review of recent findings.
Kotlar Alex V et al. European journal of medical genetics 2015 Oct (Posted: Nov 19, 2015 11AM)

Evidence of Mitochondrial Dysfunction within the Complex Genetic Etiology of Schizophrenia.
Hjelm Brooke E et al. Molecular neuropsychiatry (4) 201-219 (Posted: Nov 19, 2015 11AM)

Schizophrenia
RS Kahn et al, Nature Reviews Disease Primers, November 2015 (Posted: Nov 19, 2015 11AM)

Evaluation of an association between plasma total homocysteine and schizophrenia by a Mendelian randomization analysis.
Numata Shusuke et al. BMC Med. Genet. 2015 54 (Posted: Aug 21, 2015 10AM)

The potential of immune biomarkers to advance personalized medicine approaches for schizophrenia.
Cox David et al. J. Nerv. Ment. Dis. 2015 May (5) 393-9 (Posted: Aug 21, 2015 10AM)

Association between NR4A2 genetic variation and schizophrenia: A comprehensive systematic review and meta-analysis.
Liu Hongmei et al. Neurosci. Lett. 2015 Jun 26. 85-90 (Posted: Aug 21, 2015 10AM)

Epigenetic signaling in schizophrenia.
Ibi Daisuke et al. Cell. Signal. 2015 Oct (10) 2131-6 (Posted: Aug 21, 2015 10AM)

New international effort to uncover schizophrenia genomics
PHG Foundation, August 20, 2015 (Posted: Aug 21, 2015 10AM)

Delta Frequency Optogenetic Stimulation of the Thalamic Nucleus Reuniens Is Sufficient to Produce Working Memory Deficits: Relevance to Schizophrenia.
Duan Aranda R et al. Biol. Psychiatry 2015 Jun 15. (12) 1098-1107 (Posted: May 31, 2015 6PM)

Gene, interrupted- How a family history of schizophrenia shaped a career
M McKenzie, Emory Rollins School of Public Health, Spring 2015 (Posted: May 04, 2015 3PM)

Association of adoptive child's thought disorders and schizophrenia spectrum disorders with their genetic liability for schizophrenia spectrum disorders, season of birth and parental Communication Deviance.
Roisko Riikka et al. Psychiatry Res 2015 Apr 30. (2-3) 434-40 (Posted: Apr 25, 2015 11AM)

GWAS, cytomegalovirus infection, and schizophrenia.
Grove Jakob et al. Curr Behav Neurosci Rep 2014 Dec 1. (4) 215-223 (Posted: Apr 17, 2015 2PM)

New NIMH strategic plan aims to focus, accelerate mental health research
NIH News, March 26, 2015 Brand (Posted: Apr 06, 2015 10AM)

The National Institute of Mental Health Strategic Plan
Brand (Posted: Apr 05, 2015 9AM)

Factor structure and heritability of endophenotypes in schizophrenia: Findings from the Consortium on the Genetics of Schizophrenia (COGS-1).
Seidman Larry J et al. Schizophr. Res. 2015 Apr (1-3) 73-9 (Posted: Apr 05, 2015 8AM)

Evaluating historical candidate genes for schizophrenia.
Farrell M S et al. Mol. Psychiatry 2015 Mar 10. (Posted: Apr 05, 2015 8AM)

Genome-wide gene pathway analysis of psychotic illness symptom dimensions based on a new schizophrenia-specific model of the OPCRIT.
Docherty Anna R et al. Schizophr. Res. 2015 Mar 13. (Posted: Apr 05, 2015 8AM)

Infection and inflammation in schizophrenia and bipolar disorder: a genome wide study for interactions with genetic variation.
Avramopoulos Dimitrios et al. PLoS ONE 2015 (3) e0116696 (Posted: Apr 05, 2015 8AM)

The importance of endophenotypes in schizophrenia research.
Braff David L et al. Schizophr. Res. 2015 Apr (1-3) 1-8 (Posted: Apr 05, 2015 8AM)

Early Onset Schizophrenia: Gender Analysis of Genome-Wide Potential Methylation.
Ali Bani Fatemi C Lement Zai et al. Clin. Chim. Acta 2015 Mar 31. (Posted: Apr 05, 2015 8AM)

Polygenic Risk Score, Parental Socioeconomic Status, Family History of Psychiatric Disorders, and the Risk for Schizophrenia: A Danish Population-Based Study and Meta-analysis.
Agerbo Esben et al. JAMA Psychiatry 2015 Apr 1. (Posted: Apr 05, 2015 8AM)

Association study of GABRG2 polymorphisms with suicidal behaviour in schizophrenia patients with alcohol use disorder.
Zai Clement C et al. Neuropsychobiology 2014 (3) 154-8 (Posted: Feb 28, 2015 8PM)

Childhood-Onset Schizophrenia
From NCATS Genetic and Rare Diseases Information Center Brand (Posted: Jan 01, 2011 0AM)


Disclaimer: Articles listed in Hot Topics of the Day are selected by Public Health Genomics Branch to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP